Santoro Rosanna

La Dr.ssa Rosanna Santoro si è laureata in Biologia e Specializzata in Genetica Medica. Dal 1994, presso il laboratorio di Epatologia, si dedica allo studio della genetica dell'ospite nei pazienti con infezione da HCV. Ha messo a punto test di diagnostica molecolare per Steatosi, Epatiti virali B e C, morbo di Wilson, colestasi gravidica, deficit di alfa-1 antitripsina, sindrome di Gilbert.

Informazioni aggiuntive

  • Pubblicazioni Scientifiche:

    Totale pubblicazioni a partire dal 2011: 21


    Anno

    2019; 8(4):

    SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.

    Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A


    2019; 14(5): e0215783

    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

    Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, C


    2018; 154(6): 1764-1777.e7

    TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

    Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C


    2018; 48(5): 564-573

    A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

    El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Bayoumi A, Boonstra A, Brouwer WP, Smedile A, Abate ML, Loglio A, Douglas MW, Khan A, Santoro R, Fischer J, Leeming DJ, Liddle C, George J, Eslam M


    2018; 13(7): e0200568

    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.

    Mangia A, Losappio R, Cenderello G, Potenza D, Mazzola M, De Stefano G, Terreni N, Copetti M, Minerva N, Piazzola V, Bacca D, Palmieri V, Sogari F, Santoro R


    2017; 46(6): 629-630

    Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.

    Mangia A, Piazzolla V, Santoro R


    2017; 46(4): 424-431

    Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

    Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G


    2016; ():

    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.

    Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M


    2016; 36(7): 971-6

    The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.

    Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM


    2014; ():

    Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study.

    Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A


    2013; 58: S476

    Effects of a new liposome-encapsulated formulation of silybin on hepatitis c virus infection

    Ripoli M., Angelico R., Piazzolla V., Santoro R., Mottola L., Petruzzellis D., Mangia A.

    2013; 59(2): 221-8

    Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

    Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C


    HCV2012 - 19th International Symposium on hepatitis C virus and related viruses 2012; Venezia 5-9 ottobre 2012: p 301

    Effects of silybin on Hepatitis C virus replications: an "in vitro" study

    Ripoli M, Piazzolla V, Mottola L, Santoro R, Petruzzellis D, Mangia A,

    2012; Ottobre 2012 - 1791: 1028a

    Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major tretated for chronic hepatitis C

    Santoro R, Piazzolla V, Mottola L, Dello Iacono N, Mangia A

    2012; 56 - 1135: s448

    IL28B CC. Genotype is associated with higher on-treatment-response rates in PTS with HCV-3: interim results of the write study

    Piazzolla V, Forte P, Francavilla R, Barbarini G, Mecenate F, Carrado M, Minerva G, Bacca D, Carretta V, Pellicelli A, Romano M, Montalto G, Zignego L, Nosotti L, De Luna A, Agostinacchio E, Cuccorese G, Luchi S, Bertino G, Santoro R, Mottola L, Petruzzel

    2011; 16(8): 1309-16

    IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients.

    Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I


    2011; 54: S525

    Lack of association between IL28B variants and HBSAG clearance after interferon treatment

    Mangia A, Santoro R, Mottola L, Fasano M, Minerva N, Bacca D, Piazzolla V, Carretta V, Termite A, Agostinacchio E, Facciorusso D, Petruzzellis D, Santantonio T

    2011; 54(4): 403A-404A

    Treatment Of Patients With Acute Hcv Monoinfection May Be Delayed After Week 24 According With Il28b Single Nucleotide Polymorphisms (Snp) Results And Independently Of Hepatitis C Virus (Hcv) Genotype

    Mangia A. et al.

    2011; ():

    Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring.

    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG


    2011; 53(2): 389-95

    Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

    Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A


    2011; 54(s1): 339-340

    Genetic predictors of steatosis and fibrosis in non alcoholic fatty liver disease (NAFLD)

    Mangia A, Mottola L, Petruzzellis D, Piazzolla V, Garrubba M, Di Paola R, Santoro R, Trischitta V, Villella M, Fanelli R, Vanni E, Seripa D, Pilotto A, Bugianesi E, Guido M, Santini SA

    {accordionfaq faqid=accordion3 faqclass="lightnessfaq defaulticon headerbackground headerborder contentbackground contentborder round5" active=0}

nuovo-css

webcamlive

Newsletter

Informativa Newsletter
  twitter   facebook   youtube   g plus